ALNY News and Press, Alnylam Pharmaceuticals Inc. From 10/31/22

Summary Alnylam's third quarter results were basically on target, with a stronger Amvuttra launch leading to more Onpattro switchovers, and some weakness in Givlaari and Oxlumo. There are still multiple credible and significant questions about whether Onpattro data will support wi...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...

Summary Alnylam missed Q3 revenue and EPS estimates, primarily due to lower-than-expected collaboration revenue. Amvuttra is off to a strong start in the United States with new patient starts doubling the previous pace of Onpattro in the first four months on the market. Analys...

- Annual Survey has Ranked Alnylam within the Top Three on the Best Employers List Since 2019 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its second place ranking in Science Magazine’s 2022 Top Employer Survey. ...

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Alnylam Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2022 Earnings Conference Call October 27, 2022 08:30 ET Company Participants Christine Lindenboom - Senior Vice President, Investor Relations and Corporate Communications Yvonne Greenstreet - Chief Executive Officer Tolga T...

RNAi therapeutics company Alnylam Pharmaceuticals ( NASDAQ: ALNY ) announced Thursday it dropped plans to begin a late study to find a potential therapy for the rare eye disorder Stargardt Disease as it evaluates the impact of the recently enacted Inflation Reduction Act in the ...

Alnylam Pharmaceuticals press release ( NASDAQ: ALNY ): Q3 Non-GAAP EPS of -$1.58 misses by $0.20 . Revenue of $264.31M (+40.9% Y/Y) misses by $27.35M . Cash, cash equivalents and marketable securities were $2.27B as of September 30, 2022 compared to $2.44B as ...

− Achieved Third Quarter 2022 Global Net Product Revenues of $232 Million for ONPATTRO ® , AMVUTTRA ® , GIVLAARI ® , and OXLUMO ® – − Strong First Full Quarter of AMVUTTRA in U.S.: Achieving $25 Million in Net Product Re...

Summary Today is a great time to invest for the long run, though the market may very likely experience more volatility before once again resuming its march higher. We expect meaningful market share gains from most if not all of our investments. Returns from here will be powere...